

**REQUEST FOR CONTINUED EXAMINATION  
(RCE) TRANSMITTAL**

Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000, provides for continued examination of an utility or plant application filed on or after June 8, 1995.  
See The American Inventors Protection Act of 1999 (AIPA).

*Application No.:* 10/024,858  
*Filing Date:* December 18, 2001  
*First Named Inventor:* Graham Leonard  
*Group Art Unit:* 1615  
*Examiner:* H. Sheikh  
*Attorney Docket No.:* P31220X2C2RS

**CERTIFICATION OF FACSIMILE TRANSMISSION**

I hereby certify that this paper is being facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

Theresa M. Munro

**FAX RECEIVED**

OCT 05 2006

Type Name of Person faxing this document

*Theresa Munro*

Signature

October 5, 2006

Date

**OFFICE OF PETITIONS**

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application.

**NOTE:** 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53 (d) (PTO/SB/29) instead of RCE to be eligible for the patent term adjustment provisions of the AIPA. See Changes to Application Examination and Provisional Application Practice, Final Rule, 65 Fed. Reg. 50192 (Aug 16, 2000); Interim Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000) 1233 Off. Gaz. Pat. Office 47 (April 11, 2000), which established RCE practice.

**1. Submission required under 37 C.F.R. § 1.114**

- a.  Previously submitted
  - i.  Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on \_\_\_\_\_.  
(Any unentered amendment(s) referred to above will be entered)
  - ii.  Consider the arguments in the Appeal Brief or Reply Brief previously filed on \_\_\_\_\_.
  - iii.  Other \_\_\_\_\_
- b.  Enclosed
  - i.  Amendment/Reply \_\_\_\_\_ pages
  - ii.  Affidavit(s)/Declaration(s) \_\_\_\_\_ pages
  - iii.  Information Disclosure Statement (IDS) 1 page
  - iv.  Form PTO 1449 1 pg. & 2 References
  - v.  Return Receipt Postcard (MPEP 503) (specifically itemized)
  - vi.  Other: Petition for Withdraw of Patent from issue (2 pages)

**2. Miscellaneous**

- a.  Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103 (c) for a period of \_\_\_\_\_ months. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.17(l) required)
- b.  Other \_\_\_\_\_

**3. FEES** The RCE fee under 37 C.F.R. § 1.117(c) is required by 37 C.F.R. § 1.114 when the RCE is filed.

- a.  The Director is hereby authorized to charge the following fees or credit any overpayments, to **Deposit Account No. 19-2570**.

General Authorization to charge any and all fees under 37 CFR 1.16 or 1.17, including petitions for extensions of time, relating to this application. (37 CFR 1.136(a)(3))

- i.  RCE fee required under 37 C.F.R. § 1.17(e). \$790.00
- ii.  ( ) Month Extension of time fee (37 C.F.R. §§ 1.136 and 1.17)
- iii.  Additional Fees
- iv.  Total Fee to be charged to Deposit Account **19-2570** **\$790.00**

**CORRESPONDENCE ADDRESS**

*Address* GLAXOSMITHKLINE  
Corporate Intellectual Property – UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
*Telephone* (610) 270-5023 *Facsimile* (610) 270-5090

n:\wj\paroxetine\P31220 Paxil CR\RCE-5.doc

**RESPECTFULLY SUBMITTED,**

*Wayne J. Dusman*  
Signature \_\_\_\_\_  
NAME Wayne J. Dusman

Registration No. 33,870